Direct accesses

  • Go to main menu
  • Go to main content
Menu
GenSight GenSight
Search the site
  • Contact
  • Careers
  • You are viewing the website in English en
  • fr
Search the site
  • Whowe are
    • Company
    • Leadership
    • Collaborations
  • Diseaseswe target
    • Diseases we target
    • Leber Hereditary Optic Neuropathy (LHON)
    • Retinitis Pigmentosa (RP)
    • Geographic Atrophy in Dry-AMD
  • Ourtechnologies
    • Technologies we are applying
    • Gene Therapy
    • Mitochondrial Targeting Sequence (MTS)
    • Optogenetics
    • Clinical development Summary
  • Investors
    • Company Overview
    • Financial press releases
    • Investor Newsletters
    • Events & presentations
    • Stock information & Financial agenda
    • Governance
    • Documentation
  • Media

Press Releases

Filter articles using the following links
  • Financial press releases
  • Events & presentations
15 Sep 2021 - 16 Sep 2021

5th Annual Cell & Gene Therapy World Asia, virtual

14 Sep 2021

Clinical Trials in Rare Diseases Conference 2021, Europe and USA, virtual conference

09 September 2021

GenSight Biologics Announces Publication Analyzing Visual Parameters of ND4-LHON Subjects before LUMEVOQ® treatment in Phase III Trials

08 Sep 2021

Ophthalmology Futures Forums – Euro Retina Virtual Forum, September 8, 2021

06 September 2021

UK MHRA grants GenSight Biologics’ LUMEVOQ® ophthalmic gene therapy Promising Innovative Medicine designation

07 Sep 2021

Redburn Gene Therapy Virtual Summit 2021

02 Sep 2021 - 04 Sep 2021

2021 ISGEDR Meeting (International Society for Genetic Eye Diseases & Retinoblastoma)

01 September 2021

Clinical Data on GenSight Biologics’ LUMEVOQ® and GS030 Gene Therapies to be Presented at 2021 ISGEDR and Several Investor and Industry Meetings in September

31 August 2021

GenSight Biologics Announces Publication of RESTORE Study Data Demonstrating Sustained Efficacy 3 Years After Unilateral Injection of LUMEVOQ®

29 July 2021

GenSight Biologics Reports Interim Financial Results for the First Half of 2021 and Provides Operational Update

  • View previous 9 articles
  • 1
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 42
  • View next 9 articles
© 2025 Gensight Biologics
  • Terms of use
  • Sitemap
  • Contact
  • Credits
  • Cookies management
Go back to the page of the page